Search - tctmd.com

Displaying 501 - 520 of 1337

Sort: Relevancy | Date

News Conference News AHA 2021

PALACS: Posterior Left Pericardiotomy Cuts Postop AF After Cardiac Surgery

Todd Neale

November 14, 2021

News Conference News AHA 2021

Tricuspid Repair During Mitral Surgery Slows Disease Progression at 2 Years

Caitlin E. Cox

November 13, 2021

News Conference News AHA 2021

AVATAR Supports Early SAVR in Asymptomatic Severe AS Patients

L.A. McKeown

November 13, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News TCT 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

Yael L. Maxwell

November 06, 2021

Presentation TCT 2021

SWISS-APERO: A Randomized Trial of the Amulet Versus Watchman FLX Devices for Left Atrial Appendage Closure

Presenter: Roberto Galea

November 06, 2021

News Conference News TCT 2021

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

Todd Neale

November 06, 2021

Presentation TCT 2021

AMULET IDE: One-Year Device Closure From a Randomized Trial of Amulet Versus Watchman for Left Atrial Appendage Occlusion

Presenter: Dhanunjaya Lakkireddy

November 05, 2021

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

Presentation TCT 2021

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Presenter: David Cohen

November 05, 2021

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

Presentation TCT 2021

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presenter: Nicolas Van Mieghem

November 05, 2021

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Todd Neale

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Presenter: Ori Ben-Yehuda

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Presenter: Joanna Chikwe

November 05, 2021

Presentation TCT 2021

Triluminate Registry: Lessons Learned for TEER Trial Design

Presenter: Georg Nickenig

November 04, 2021

News Daily News

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

Yael L. Maxwell

November 03, 2021

News Daily News

Bioresorbable PFO/ASD Closure Device Shows Promise, but More Research Needed

Yael L. Maxwell

November 02, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for October 2021

Shelley Wood

November 02, 2021

News Daily News

Tailored TAVI: Standardizing Balloon Pressures May Curb Operator Angst

L.A. McKeown

October 28, 2021

Advertisement

PALACS: Posterior Left Pericardiotomy Cuts Postop AF After Cardiac Surgery

Tricuspid Repair During Mitral Surgery Slows Disease Progression at 2 Years

AVATAR Supports Early SAVR in Asymptomatic Severe AS Patients

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

SWISS-APERO: A Randomized Trial of the Amulet Versus Watchman FLX Devices for Left Atrial Appendage Closure

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

AMULET IDE: One-Year Device Closure From a Randomized Trial of Amulet Versus Watchman for Left Atrial Appendage Occlusion

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Triluminate Registry: Lessons Learned for TEER Trial Design

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

Bioresorbable PFO/ASD Closure Device Shows Promise, but More Research Needed

TCTMD’s Top 10 Most Popular Stories for October 2021

Tailored TAVI: Standardizing Balloon Pressures May Curb Operator Angst

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content